Sunshine Heart Announces Presentations at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

EDEN PRAIRIE, Minn., May 14, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced that Dr. Patrick Verta, Sunshine Heart's Chief Medical Officer, will be presenting two posters at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), May 17-20 at the Megaron Athens International Conference Centre in Athens, Greece.

Additional information on the poster presentations can be found below and posters can be accessed at www.sunshineheart.com following the presentations on May 17th.

Poster Presentations:
Date/Time:	Saturday, May 17, 2014, 8:30 AM - 6:00 PM
Location:	Poster Area
Session Title:	Poster with discussant session
Presentation Title:	Preliminary results from the C-Pulse® System European Multicenter Study
Authors:	Holger Hotz, MD, Leonhard Bruch, MD, Jan Schmitto, MD, Thomas Krabatsch, MD
Abstract Number:	P256
Date/Time:	Saturday, May 17, 2014, 8:30 AM - 6:00 PM
Location:	Poster Area
Session Title:	Poster with discussant session
Presentation Title:	Improvements in Myocardial Perfusion Observed in Patients Supported with the C-Pulse® Counterpulsation Device
Authors:	Renzo Cecere, MD, Marc Hickeson, MD, Nadia Giannetti, MD
Abstract Number:	P260

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.